6. Definitions and results of survival and/or relapse analysis in other antigen‐specific immunotherapy studies.
| Study | Analysed | Definition | Results |
| Antonilli 2016 | yes | recurrence rate | recurrence rate: n = 2 |
| Berinstein 2012 | yes | time to progression (study day 0 to relapse) | median time to progression > 8 months (range 4 to > 9) |
| Berinstein 2013 | no | ||
| Brossart 2000 | no | ||
| Chianese‐Bullock 2008 | no | ||
| Chu 2012 | yes | progression‐free survival (first vaccination to relapse)/overall survival (first vaccination to death/last follow‐up) | 3‐year progression‐free survival: arm 1 vs arm 2, 40% vs 80% (P = 0.17) 3‐year overall survival: arm 1 vs arm 2, 80% vs 100% (P = 1.00) |
| Diefenbach 2008 | yes | time to progression (last chemo to relapse) | median time to progression 13.0 months (95% CI 11.2 to not reached) |
| Dijkgraaf 2015 | yes | progression‐free survival: time from start of therapy until progression in weeks overall survival: time from start of therapy until death in weeks |
Progression‐free survival cohort 3: 8 to 36 (median 13) Overall survival cohort 3: 12 to 48 (median 37) |
| Dhodapkar 2012 | no | ||
| Freedman 1998 | yes | progression‐free interval; survival | median progression‐free interval: 4 months (95% CI 1.9 to 7.6) median survival: 13.3. months (95% CI 1.5 to 30.8) |
| Galanis 2010 | yes | overall survival | median overall survival: 12.2 months (range 1.3 to 38.4) |
| Goh 2013 | yes | progression‐free survival; overall survival | median progression‐free survival vaccine vs standard of care 365 days vs 321 days overall survival: not reported |
| Gray 2016 | yes | progression‐free survival overall survival |
progression‐free survival: 13 months (Cvac) vs 9 months (standard of care) overall survival: median not reached at 43 months in both study arms. |
| Gribben 2005 | no | ||
| Gulley 2008 | yes | progression‐free survival; overall survival | progression‐free survival: 9, 18, 19+ months; OS: 6, 19+, 21 months |
| Imhof 2013 | yes | time to progression (first vaccination to relapse)/overall survival (first vaccination to death) | not reported |
| Kaumaya 2009 | no | ||
| Kawano 2014 | yes | median survival time | median survival time overall (n = 42): 19.1 months median survival time platinum‐sensitive (n = 17): 39.3 months median survival time platinum‐resistant (n = 25): 16.2 months |
| Kobayashi 2014 | yes | median survival time from first vaccination | median survival time 14.5 months |
| Le 2012 | no | ||
| Leffers 2009a | yes | disease‐specific survival (diagnosis to death of ovarian cancer) | median disease‐specific survival participants vs historical controls: 44.0 months vs 47.4 months |
| Lennerz 2014 | no | ||
| Letsch 2011 | no | ||
| MacLean 1996 | yes | survival (trial entry to death) | median survival: 12.7 months |
| MacLean 1992 | no | ||
| Mohebtash 2011 | yes | progression‐free survival/overall survival | median progression‐free survival: 2 months (range 1 to 36) median overall survival: 15.5 months (range 1.5 to > 57.0) |
| Morse 2011 | yes | overall survival | median overall survival: not reached (range 289 to 1115+ days) |
| Nishikawa 2006 | no | ||
| O'Cearbhaill 2016 | yes | progression‐free survival: time from the end of adjuvant chemotherapy until disease progression | not adequately described |
| Odunsi 2007 | yes | time to progression (first vaccination to relapse) | median time to progression: 19.0 months (95% CI 9.0 to not reached) |
| Odunsi 2012 | yes | progression‐free survival/overall survival | median progression‐free survival: 21 months (95% CI 16 to 29 months) median overall survival: 48 months (95% CI not estimable) |
| Odunsi 2014 | no | ||
| Ohno 2009 | no | ||
| Peethambaram 2009 | yes | time to progression | median time to progression: 14.0 (range 12.1 to 18.3) |
| Rahma 2012 | yes | progression‐free survival (date on study to date of progression) overall survival (date on study to date of death or last follow‐up) |
median progression‐free survival: 4.2 vs 8.7 months median overall survival: 40.8 vs 29.6 months |
| Sabbatini 2000 | yes | time to progression (trial entry to relapse) | median time to progression: 6 months (range 2 to 17) |
| Sabbatini 2007 | yes | time to progression (first vaccination to relapse) | median time to progression: 4.2 months (95% CI 2.7 to 8.5) |
| Sabbatini 2012 | yes | time to progression | no differences between cohorts (numbers not reported) |
| Sabbatini 2017 | yes | progression‐free survival: time from randomisation to first clinical, biochemical, or radiological evidence of progression overall survival: time from study untill death. |
progression‐free survival: 5.9 months vaccine + OPT‐821 vs 6.5 months OPT‐821 only overall survival: 46.5 months vaccine + OPT‐821 vs 46.2 months OPT‐821 only |
| Sandmaier 1999 | no | ||
| Suzuki 2016 | yes | time to progression/overall survival | time of progression: not reported overall survival after 12 months of all patients: 20.6% |
| Takeoka 2017 | no | ||
| Takeuchi 2013 | yes | overall survival | median overall survival: HLA‐A24 5 months (range 30 to 623 days), HLA‐A02 9 months (range 54 to 921 days) |
| Tsuda 2004 | no | ||
| Vermeij 2012 | no |
CI: confidence interval.